Umjovo wehepatitis A

From Wikipedia
Jump to navigation Jump to search

Umjovo wehepatitis A ngumjovo lovikela ihepatitis A.[1] Usebente kahle kakhulu kubantfu labagulako labangu 95% kantsi ube khona lokungenani iminyaka lelishumi nesihlanu nesikhatsi umuntfu langahle asiphile.[1][2] Uma uniketwa, emadosi lamabili ayaconywa ekucaleni ngemuva kwemnyaka munye. Uniketwa ngekukujova emsipheni.[1]

Inhlangano Yetemphilo Mhlabawonkhe (i-WHO) incoma imijova lesebenta ndzawotonkhe etindzaweni lapho ungakavami kangako. Lapho lesifo sijwayeleke khona imijovo lesabalele ayinconywa njengoba bonkhe bantfu bavame kungenwa kusuleleka ngetifo ngemntfwana.[1] Sikhungo Lesilawula Nalesivikela Tifo (i-CDC) incoma kujovwa kwebantfu labadzala labasengotini kakhulu nabo bonkhe bantfwana.[3]

Imitselela lemibi lecacile ayikavamisi kwenteka. Kuba khona tinhlungu kulelicala lelijoviwe lobulinganiselwa ku-15% kubantfwana nehhafu yebantfu labadzala. Imijovo leminyenti yehepatitis A icuketse emagciwane langaphili ngalesikhatsi leminye inemagciwane langenamandla. Lena lenemagciwane lengenamandla akufanele itsatfwe ngalesikhatsi ukhulelwe noma kulabo labanemasotja langasebenti kahle. Kwakheka lokumbalwa kwenhlanganisela yehepatitis A mhlawumbe nehepatitis B noma umjovo wethayifodi.[1]

Umjovo wekucala we-A wavunyelwa e-Europe nga-1991 nase United States nga-1995.[4] KukuLuhla Lwemitsi Lebalulekile Lwenhlangano Yetemphilo Mhlabawonkhe, umutsi lobaluleke kakhulu lodzingekako kuloluhlelo lolusisekelo lwetemphilo.[5] E-United States ubita emkhatsini wa-50 na 100 USD.[6] Template:Drugbox

Emareferensi[hlela | edit source]

  1. 1.0 1.1 1.2 1.3 1.4 "WHO position paper on hepatitis A vaccines – June 2012" (PDF). Wkly Epidemiol Rec. 87 (28/29): 261-76. 2012 Jul 13. PMID 22905367.
  2. Ott JJ, Irving G, Wiersma ST (December 2012). "Long-term protective effects of hepatitis A vaccines. A systematic review". Vaccine. 31 (1): 3–11. doi:10.1016/j.vaccine.2012.04.104. PMID 22609026.
  3. "Hepatitis A In-Short". CDC. July 25, 2014. Retrieved 7 December 2015.
  4. Patravale, Vandana; Dandekar, Prajakta; Jain, Ratnesh (2012). Nanoparticulate drug delivery perspectives on the transition from laboratory to market (1. publ. ed.). Oxford: Woodhead Pub. p. 212. ISBN 9781908818195.
  5. "19th WHO Model List of Essential Medicines (April 2015)" (PDF). WHO. April 2015. Retrieved May 10, 2015.
  6. Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 314. ISBN 9781284057560.